Consulting with healthcare providers familiar with peptide research can help contextualize individual risks and benefits
BPC-157 ships to the United States and 20+ countries including Canada, the United Kingdom, Australia, New Zealand, Ireland, Singapore, the Philippines, and South Africa

Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides
What we know about extended use The longest controlled human trials ran for 12 weeks
These individuals can receive an injectable form of the vitamin, which altogether bypasses the gastrointestinal tract
The gut and immune system also depend on microbes